Consequently, MS-444 reduces the expression of HuR targets such as COX-2, cyclin D1, and VEGF, leading to impaired tumor cell proliferation, induction of apoptosis, and suppression of tumor growth in colorectal and pancreatic cancer models. Here, ELAVL1 is linked to neoplasm.